Patrys Ltd (ASX: PAB) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Patrys Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $14.40 million
P/E Ratio N/A
Dividend Yield 0.00%
Shares Outstanding 2.06 billion
Earnings per share -0.003
Dividend per share N/A
Year To Date Return -12.50%
Earnings Yield N/A
Franking -
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • Patrys Ltd (ASX: PAB)
    Latest News

    a doctor with stethoscope around neck sits as a computer with head in hand, looking despondent.
    Healthcare Shares

    Here's why the Patrys (ASX:PAB) share price is tumbling 16% today

    Investors tend to keep a keen eye on clinical trial progress.

    Read more »

    A medical researcher in a white coat holds laboratory equipment and smiles.
    Share Market News

    Here's why the Patrys (ASX: PAB) share price is climbing 13% today

    This small-cap ASX share revealed some exciting news today.

    Read more »

    ASX shares fund manager martin hickson
    Ask a Fund Manager

    Why we avoid mining and biotech ASX shares: fund manager

    Ask A Fund Manager: 1851 Capital's Martin Hickson also reveals the telecommunications company that gets paid to build its products.

    Read more »

    PAB ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About Patrys Ltd

    Patrys Ltd focuses on the development of natural human antibody-based therapies for the treatment of cancer. The company's product includes Deoxymab 3E10, PAT-SC1, PAT-DX1 PAT-DX1-NP, PAT-DX3, and PAT-LM1. Its main technology is Deoxymab 3E10, a DNA damage repair (DDR) antibody that penetrates live cell nuclei and inhibits key mechanisms of DNA repair in target cancer cells.

    PAB Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    21 Jun 2024 $0.01 $0.00 0.00% 6,183,944 $0.01 $0.01 $0.01
    20 Jun 2024 $0.01 $0.00 0.00% 398,930 $0.01 $0.01 $0.01
    19 Jun 2024 $0.01 $0.00 0.00% 1,161,042 $0.01 $0.01 $0.01
    18 Jun 2024 $0.01 $0.00 0.00% 453,131 $0.01 $0.01 $0.01
    17 Jun 2024 $0.01 $0.00 0.00% 175,574 $0.01 $0.01 $0.01
    14 Jun 2024 $0.01 $0.00 0.00% 66,352 $0.01 $0.01 $0.01
    13 Jun 2024 $0.01 $0.00 0.00% 1,050,000 $0.01 $0.01 $0.01
    12 Jun 2024 $0.01 $0.00 0.00% 413,435 $0.01 $0.01 $0.01
    11 Jun 2024 $0.01 $0.00 0.00% 1,300,423 $0.01 $0.01 $0.01
    07 Jun 2024 $0.01 $0.00 0.00% 2,996,188 $0.01 $0.01 $0.01
    06 Jun 2024 $0.01 $0.00 0.00% 2,851 $0.01 $0.01 $0.01
    05 Jun 2024 $0.01 $0.00 0.00% 12,479 $0.01 $0.01 $0.01
    04 Jun 2024 $0.01 $0.00 0.00% 575,392 $0.01 $0.01 $0.01
    03 Jun 2024 $0.01 $0.00 0.00% 700,016 $0.01 $0.01 $0.01
    31 May 2024 $0.01 $0.00 0.00% 1,899,578 $0.01 $0.01 $0.01
    30 May 2024 $0.01 $0.00 0.00% 118,900 $0.01 $0.01 $0.01
    29 May 2024 $0.01 $0.00 0.00% 240,429 $0.01 $0.01 $0.01
    28 May 2024 $0.01 $0.00 0.00% 2,969,215 $0.01 $0.01 $0.01
    27 May 2024 $0.01 $0.00 0.00% 1,000 $0.01 $0.01 $0.01
    24 May 2024 $0.01 $0.00 0.00% 167,000 $0.01 $0.01 $0.01
    23 May 2024 $0.01 $0.00 0.00% 2,337,837 $0.01 $0.01 $0.01

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    15 Mar 2024 Pamela Klein Expiry 250,000 $2,500
    Options expired. As per announcement on 22-03-2024
    15 Dec 2023 James Campbell Expiry 401,544 $3,212
    Options expired.
    22 Nov 2023 Michael Stork Expiry 4,000,000 $36,000
    Options expired.
    22 Nov 2023 James Campbell Expiry 10,000,000 $90,000
    Options expired.
    04 Aug 2023 James Campbell Expiry 399,415 $3,994
    Options expired.

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Dr James Campbell Chief Executive OfficerManaging Director Nov 2014
    Dr Campbell has more than 20 years of international biotechnology research, management and leadership experience and has been involved in the creation and/or transformation of multiple successful Australian and international biotechnology companies. Dr. Campbell was a foundation executive of Evolve Biosystems, and has assisted private biotechnology companies in Australia, New Zealand and the USA with capital raising and partnering negotiations. Dr. Campbell sits on the Board of AusBiotech, Australia's peak industry body for biotechnology
    Mr Michael Stork Non-Executive DirectorNon-Executive Deputy Chairman Feb 2007
    Mr Stork was the Managing Director of Stork Holdings Ltd, an Investment Holding company active in the Canadian technology start-up sector.Mr. Stork was on the Board of Governors of the University of Waterloo and is the Chair of the Waterloo Accelerator Centre, a technology company incubator affiliated with the University.He was the Chair of Spartan Biosciences Inc.,an Ottawa based DNA analytics company,the Chair of Dejero Labs Inc. a Waterloo based broadcast technology company,and active on the Boards of a number of other leading Canadian technology start-up companies.He is Chair of Risk Committee.
    Mr Stefan Ross Company Secretary Oct 2021
    Mr Ross has over 10 years of experience in accounting and secretarial services for ASX listed companies. His experience includes ASX compliance, corporate governance control and implementation, statutory financial reporting, shareholder meeting requirements, capital raising management, and board and secretarial support.
    Dr Pamela M Klein Non-Executive Director Oct 2019
    Dr Klein has a track record as an executive over more than 20 years in the oncology and biopharmaceutical industry. She is currently on the Board of Directors for Argenx, a dual-listed (Euronext Brussels and NASDAQ), clinical-stage therapeutic antibody company developing novel drugs in severe autoimmune disease. She is also on the Board of IMab, F-Star,Sardona and ONA. Dr. Klein is the Principal and Founder of PMK BioResearch, which offers strategic consulting in oncology drug development.
    Dr Charmaine Gittleson Non-Executive ChairmanNon-Executive Director Nov 2022
    Dr Gittleson is the former Chief Medical Officer of CSL Limited with more than 20 years of experience in pharmaceutical development in Australia and the USA.Dr. Gittleson's spans many aspects of the pharmaceutical industry, from drug development and clinical research through to strategic planning and executive management.Dr. Gittleson has been involved in drug development programs across a wide range of different therapeutic areas, and has worked with regulators in key markets such as the US,EU,Asia Pacific,Japan and South America.where she has been actively involved in strategy development, capital raising and Board renewal.He is Member of risk Committee.
    Deanne Greenwood Vice President Business Development & Intellectual Property
    -
    Rebecca Tunstall Vice President Corporate Development
    -
    Valentina Dubljevic Vice President Research & Development
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    Dr Dax Marcus Calder 128,200,000 6.23%
    Citicorp Nominees Pty Limited 105,576,681 5.13%
    Stork Holdings 2010 Ltd 98,773,814 4.80%
    Dax Calder Pty Ltd 65,000,000 3.16%
    Mr Mladen Marusic 57,472,983 2.79%
    Kemast Investments Pty Ltd <Km Stokes SF No 1 A/C> 39,814,272 1.94%
    Estelleanne Pty Ltd 35,500,000 1.73%
    Marginata Pty Ltd <Roy Bolton Super Fund A/C> 31,000,000 1.51%
    Altum Trustees Limited <Mk Pension Plan 473278 A/C> 28,049,888 1.36%
    Staffwear Pty Ltd <Dax Calder Super Fund A/C> 27,000,000 1.31%
    Altum Trustees Ltd <The Konda Family A/C> 26,499,994 1.29%
    Mr Vinh Tran 20,205,520 0.98%
    Mr Justin Frank Puddick 17,000,000 0.83%
    Yale University 16,116,324 0.78%
    Towns Corporation Pty Ltd <Pae Family A/C> 15,482,960 0.75%
    Edstop Pty Limited <Superannuation Fund A/C> 14,771,223 0.72%
    Mr Craig Geoffrey Thomas 14,062,036 0.68%
    Mr Thomas Edgar Edmunds & Mrs Susan Rae Edmunds <The Edmunds Family SF A/C> 11,500,000 0.56%
    Dr James Campbell & Dr Kelly Windmill 11,383,125 0.55%
    Mr Vishal Gumber 10,333,733 0.50%

    Profile

    since

    Note